Exhibit 99.1 Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments New York, NY, May 7, 2024 (GLOBE NEWSWIRE) – Y-mAbs Therapeutics, Inc. (the "Company" or "Y- mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2024. "We continued to make meanin ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2023 Earnings Conference Call March 1, 2024 8:00 AM ET Company Participants Courtney Dugan - Vice President, Head of Investor Relations Michael Rossi - President and Chief Executive Officer Sue Smith - Chief Commercial Officer Vignesh Rajah - Chief Medical Officer Bo Kruse - Chief Financial Officer Conference Call Participants Alec Stranahan - Bank of America David Nierengarten - Wedbush Securities Lukas Shumway - BMO Capital Markets Operator Good morning and welco ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38650 Y-mAbs Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 47-4619612 (State ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2023 Results Conference Call November 14, 2023 9:00 AM ET Company Participants Courtney Dugan - Vice President of Investor Relations Michael Rossi - President and Chief Executive Officer Thomas Gad - Chief Business Officer Bo Kruse - Chief Financial Officer Sue Smith - Chief Commercial Officer Steen Lisby - Chief Scientific Officer Conference Call Participants Alec Stranahan - Bank of America Charles Zhu - Guggenheim Bill Maughan - Canaccord Genuity Mike Ulz - Morg ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38650 Y-mAbs Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction o ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q2 2023 Earnings Call Transcript August 11, 2023 9:00 AM ET Company Participants Courtney Dugan - Head of IR Thomas Gad - Founder, President & Interim CEO Vignesh Rajah - CMO Sue Smith - CCO Bo Kruse - CFO Conference Call Participants Alec Stranahan - Bank of America Charles Zhu - Guggenheim Securities Mike Ulz - Morgan Stanley Bill Maughan - Canaccord Genuity Tessa Romero - JP Morgan Luke Shumway - BMO Capital Markets Operator Good morning, and welcome to the Y-mAbs ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38650 Y-mAbs Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I. ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2023 Earnings Conference Call May 9, 2023 9:00 AM ET Company Participants Thomas Gad - Founder, President, Interim Chief Executive Officer Sue Smith - Senior Vice President and Chief Commercial Officer Vignesh Rajah - Senior Vice President and Chief Medical Officer Bo Kruse - Chief Financial Officer, Treasurer, and Secretary Conference Call Participants William Maughan - Canaccord Genuity Mike Ulz - Morgan Stanley Charles Zhu - Guggenheim Securities Tessa Romero - ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38650 Y-mAbs Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2022 Earnings Conference Call March 31, 2023 9:00 AM ET Company Participants Thomas Gad - Founder, Interim CEO & President Sue Smith - SVP & Chief Commercial Officer Bo Kruse - EVP, Secretary, Treasurer & CFO Vignesh Rajah - Chief Medical Officer Conference Call Participants Alec Stranahan - Bank of America Etzer Darout - BMO Capital Markets William Maughan - Canaccord Genuity Taylor Hanley - JPMorgan Edouard Mullarky - Guggenheim Securities Operator Good mornin ...